Sex Differences in Adverse Reactions to an Inactivated SARS-CoV-2 Vaccine Among Medical Staff in China

Jian-Sheng Zhu1†, Mei-Xian Zhang2†, Ching-Wen Chien3, Wei-Ying Yang4, Gui-Feng Shi5, Shulin Qiu6, Tao-Hsin Tung2* and Hai-Xiao Chen7*

1 Department of Infectious Diseases, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China, 2 Evidence-Based Medicine Center, Public Laboratory, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China, 3 Institute for Hospital Management, Tsing Hua University, Shenzhen, China, 4 Department of Intensive Care Unit, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China, 5 Department of Preventive Health Care, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China, 6 Institute for Hospital Management, Tsinghua University, Shenzhen Campus, Shenzhen, China, 7 Department of Orthopedics, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China

*Correspondence:
Tao-Hsin Tung
ch2876@yeah.net
Hai-Xiao Chen
chenhx@enzemed.com

† These authors have contributed equally to this work

Objective: We investigated whether there were sex differences in adverse reactions to an inactivated SARS-CoV-2 vaccine among medical staff in China.

Methods: From 24 February to 7 March 2021 an online cross-sectional survey was conducted with a self-administered COVID-19 vaccine questionnaire among medical staff in Taizhou, China. In total, 1397 interviewees (1,107 women and 290 men) participated in the survey.

Results: In our study, 178 (16.1%) women and 23 (7.9%) men reported adverse reactions following their first vaccination, and 169 (15.3%) women and 35 (12.1%) men reported adverse reactions following their second vaccination. After adjusting for confounding factors, adverse reactions to other vaccines, worry about adverse reactions, knowledge of the inactivated vaccine being used in the hospital, taking the vaccine for one’s family proactively and receiving an influenza vaccination were significantly related to adverse reactions to both injections in women. In contrast, in men, concerns about adverse reactions independently increased the risk of adverse reactions following either vaccination, and a history of adverse reactions to other vaccines also increased the risk of adverse reactions to both injections.

Conclusions: Sex differences in the frequency of reported adverse reactions to an inactivated SARS-CoV-2 vaccine and potential factors were demonstrated in a sample of medical staff.

Keywords: adverse reaction, sex difference, SARS-CoV-2, COVID-19, inactivated vaccine
INTRODUCTION

Coronavirus disease 2019 (COVID-19) has swept across the world since the discovery of the novel coronavirus in Wuhan in December 2019. Vaccination to prevent severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection is considered the most promising approach for controlling the pandemic. As of 1 June 2021, at least 13 different vaccines (across four platforms) have been administered, and six different vaccines have been listed for WHO Emergency Use Listing (EUL) (1), including the Pfizer/BioNTech Comirnaty vaccine, the AstraZeneca vaccine (AZD1222), the Janssen vaccine (Ad26.COV 2.S), the Moderna COVID-19 vaccine (mRNA-1273), the Sinopharm vaccine, and the Sinovac-CoronaVac. These vaccines have been demonstrated to be safe and efficacious. In China, two inactivated virus vaccines (the Sinopharm vaccine and the Sinovac-CoronaVac) were the first approved for mass vaccination. Although vaccines are widely available and vaccination rates are rising, people remain reluctant to get vaccinated immediately. Following a number of severe cases of blood clots after vaccination, some European countries have temporarily suspended AstraZeneca (AZD1222) vaccinations either fully or partially due to fear regarding thrombosis (2). Therefore, there is an urgent need to monitor and evaluate the safety of post-marketing vaccines as soon as possible.

It has been found that COVID-19 produces more severe symptoms and higher mortality among men than among women (3). Given the natural differences between two genders, women have stronger immune responses to foreign antigens and to self-antigens than men (4). Sex disparity should be taken into account in treatment and vaccine development. According to experience in monitoring adverse reactions to vaccines, many vaccines have shown sex differences (5, 6). Women tend to be more sensitive to vaccine reactions and are more prone to frequent and severe adverse effects. However, few studies to date have reported adverse events by sex, and very few analyses have evaluated sex differences in regard to the safety of SARS-CoV-2 vaccines.

Our previous real-world observational study indicated that the CoronaVac vaccine is safe because of the low proportion of self-reported adverse reactions (7). In this study we aimed to further explore sex-specific differences in adverse reactions to the vaccine, and to identify potential factors related to adverse reactions.

MATERIALS AND METHODS

Study Design and Population

A cross-sectional survey was conducted among medical staff via the largest online survey platform (Wen-Juan-Xing) in China from 24 February to 7 March 2021. The inclusion criteria were all health professionals and administrative support staff aged 18–60 years who worked and were vaccinated with the Sinovac-CoronaVac COVID-19 vaccine at a tertiary hospital. Staff with an allergic constitution, neurological disorders including seizures and encephalopathy, severe chronic disease, or immunodeficiency disease as well as lactating/pregnant women were excluded. The details of the study design have previously been described (4). The interviewees received an invitation message or email to participate in the survey once or twice. Among the 3013 staff who completed their vaccination with two doses, a total of 1,397 interviewees responded to the questionnaire, including 1107 (79.2%) women and 290 (20.8%) men. The response rate was 46.4%. This study was exempted from informed consent and was approved by the Ethics Committee of Taizhou Hospital of Zhejiang Province (Approval number: K20210217) in China. All procedures were performed in accordance with the guidelines of our institutional ethics committee and adhered to the tenets of the Declaration of Helsinki. All participants’ information was anonymous.

Questionnaire

The structured questionnaire used in this study was shown in the Supplementary Material. Solicited and unsolicited local reactions and systemic adverse events during the period of one week following vaccination were collected. Local adverse reactions included adverse reactions at the injection site, such as pain, induration, redness, swelling, or itching. Solicited systemic adverse reactions included muscle pain, fatigue, headache and/or dizziness, fever, vomiting, diarrhea, appetite impairment, nausea, allergic reaction, urticaria, rash, severe fever, lymphadenopathy, cough, throat pain, stuffy, and runny nose. The unsolicited adverse reactions included other adverse reactions with an open-text response option in the questionnaire, such as menstruation, chest pain, and numbness of limbs, which were absent or seldom in the manual. Knowledge of the inactivated vaccine being used in the hospital was measured by the following question: “What platform of the COVID-19 vaccine do you think is being used in our hospital?” Attitudes towards the COVID-19 vaccine were tested by the questions “If conditions permit, will you take the COVID-19 vaccine for your family proactively?” and “Are you concerned about adverse effects of the COVID-19 vaccine?” History of adverse reactions to other vaccines, influenza vaccination, allergies, and underlying diseases was classified as yes or no. Health status and sleep quality before vaccination were categorized as good or bad. Positions were grouped into health professionals (doctors, nurses, medical technicians or pharmacists) and administrative support staff. Overweight and obesity were defined as a BMI greater than or equal to 24 kg/m² according to Chinese criteria.

Statistical Analysis

Categorical variables of adverse reactions and basic characteristics are displayed as counts and percentages in women and men; the chi-square test was used to initially assess possible influencing factors of adverse reactions post vaccination for each sex. Multinomial logistic regression is an extension of the (binary) logistic regression if the categorical dependent outcome has more than two levels. This model was then applied to identify the influencing factors of adverse effects, and the odds ratio (OR) and 95% confidence interval (CI) were calculated. All data were analyzed using IBM SPSS Statistics software (version 22.0; SPSS Inc., Chicago, IL, USA). A p-value of <0.05 was considered to represent a statistically significant difference among test populations.
RESULTS

Basic Characteristics of the Study Population
Of the 3,013 vaccinated medical staff, 1,397 completed the questionnaire for a response rate of 46.4%. The respondents included 1,107 (79.2%) women and 290 (20.8%) men. The proportions of administrative support staff (31.0 vs. 20.4%, \( P < 0.001 \)) and graduates (27.2 vs. 5.2%, \( P < 0.001 \)) were higher in men than in women. There were also larger proportions of overweight (56.6 vs. 20.9%, \( P < 0.001 \)), underlying diseases (19.7 vs. 7.9%, \( P < 0.001 \)), and taking medication before vaccination (11.0 vs. 4.3%, \( P < 0.001 \)) among men than among women. However, men were more likely to report good health status (96.2 vs. 91.1%, \( P = 0.004 \)) and sleep quality before vaccination (81.0 vs. 75.2%, \( P = 0.039 \)), and have positive attitudes towards vaccination for their family proactively (80.7 vs. 70.6%, \( P = 0.001 \)) than women. Women were younger (mean age: 34.7 ± 8.6 years vs. 38.7 ± 9.9 years, \( P < 0.001 \)) and more likely to worry about adverse reactions (57.4 vs. 41.0%, \( P < 0.001 \)) than men.

Sex Differences in Adverse Reactions Post Vaccination
As shown in Table 1, a total of 474 adverse reactions after the first dose were reported in 178 (16.1%) women, and 381 adverse reactions after the second dose were reported in 169 (15.3%) men. A total of 51 adverse reactions after the first dose were reported in 23 (7.9%) men, and 76 adverse reactions after the second dose were reported in 35 (12.1%) men. The most common adverse reaction was localized pain at the injection site, which accounted for 65.2% of the first adverse reactions and 73.4% of the second adverse reactions in women. The corresponding figures were 56.5 and 71.4%, respectively, in men. The most common systemic adverse reactions post-vaccination were muscle pain, fatigue, and headache and/or dizziness, with higher frequencies in women than in men. Sex differences were also observed for other solicited and non-solicited adverse reactions. All adverse reactions were mild and transient (Table 1).

Factors Associated With Adverse Reactions in Women and Men
Table 2 indicates the sex-specific frequencies of adverse effects after one or two vaccinations using univariate analysis. In women, a history of adverse reactions to other vaccines, concerns about adverse reactions, knowledge of the inactivated vaccine being used in the hospital, taking vaccines for family proactively, and getting an influenza vaccine for one's family proactively (80.7 vs. 70.6%, \( P = 0.003 \)), were significantly related to adverse reactions from vaccination; adverse reactions to other vaccines, worry about adverse reactions, knowledge of the inactivated vaccine being used in the hospital, taking the vaccine for one's family proactively, and getting an influenza vaccine were significantly related to adverse reactions to both injections in women. In contrast, concerns regarding adverse reactions independently increased the risk of adverse reactions following vaccination (OR = 6.79, 95% CI: 2.66–17.37), and a history of adverse reactions to other vaccines increased the risk of adverse reactions to both injections in men (OR = 31.30, 95% CI: 7.35–133.35). In addition, there was a borderline association between overweight and adverse reactions to both injections in men (OR = 4.09, 95% CI: 0.80–20.98, \( P = 0.091 \)).

DISCUSSION

Clinical Implications
To the best of our knowledge, although previous studies have indicated the disparity of sex in adverse reactions to a number of vaccines (8, 9), few studies have assessed sex-specific differences in adverse reactions to an inactivated SARS-CoV-2 vaccine in active surveillance. This study was conducted with 1,107 women and 290 men who worked at a hospital in China during the period of emergency use of the vaccine. Our findings showed that the frequency of overall adverse reactions was higher in women than in men, regardless of whether it was the first or second injection. The most common adverse reaction was localized pain at the injection site, followed by muscle pain, fatigue, and headache and/or dizziness in both women and men. Almost all types of adverse reactions were more common in women than in men. These findings related to sex differences were similar to those observed regarding other vaccines against influenza, hepatitis B, and yellow fever (10). A systematic review published in 2019 also showed a higher frequency of adverse events in women after influenza vaccination (5), particularly local reactions. A real-world study based on the national post-marketing surveillance data for the Pfizer-BioNTech and Moderna COVID-19 vaccines in the United States found that more females reported adverse events following COVID-19 vaccination, compared to males, but males were more likely to experience serious adverse events, death, and hospitalization than females (11). More women developed anaphylaxis reactions to the Pfizer-BioNTech vaccine in U.S. (12, 13), UK (14) and Japan (15). The sex disparity of adverse reactions was also observed following AstraZeneca (AZD1222) Vaccine or BNT162b2 COVID-19 Vaccine in South Korea (16, 17). A retrospective descriptive study using spontaneous reports showed that thrombotic adverse reactions were associated with the COVID-19 AstraZeneca vaccine, in which approximately
| Adverse reactions                           | Women (n = 1107) | Men (n = 290) |
|--------------------------------------------|------------------|---------------|
|                                            | After first dose |               |
|                                            | After second dose|               |
|                                            | No.  Frequency (%) Proportion (%) | No.  Frequency (%) Proportion (%) |
| Total adverse reactions                    | 178 16.1 100     | 23 7.9 100    |
| Solicited adverse reactions                |                  |               |
| Injection site adverse reactions           | 116 10.5 65.2    | 13 4.5 56.5   |
| (Pain, induration, redness, swelling, or itch) | 124 11.2 73.4    | 25 8.6 71.4   |
| Systemic adverse reactions                 |                  |               |
| Muscle pain                                | 98 8.9 55.1      | 10 3.4 43.5   |
| Fatigue                                    | 96 8.7 53.9      | 9 3.1 39.1    |
| Headache, Dizziness                        | 69 6.2 38.8      | 7 2.4 30.4    |
| Fever                                      | 29 2.6 16.3      | 3 1.0 13.0    |
| Vomiting, Diarrhea                         | 16 1.4 9.0       | 3 1.0 13.0    |
| Appetite impaired, Nausea                  | 15 1.4 8.4       | 0 0 0         |
| Allergic reaction, urticaria, rash         | 10 0.9 5.6       | 2 0.7 8.7     |
| Stuffy, runny nose                         | 9 0.8 5.1        | 1 0.3 4.3     |
| Cough, Throat pain                         | 8 0.7 4.5        | 2 0.7 8.7     |
| Lymphadenopathy                            | 2 0.2 1.1        | 1 0.3 4.3     |
| Non-solicited adverse reactions            |                  |               |
| (Menstruation, chest pain, numbness of limbs) | 6 0.5 3.4        | 0 0 0         |
|                                             |                  |               |
### TABLE 2 | Univariate analysis of associated factors for adverse reactions in women and men.

| Variables                              | n    | Adverse reactions in women (n = 1107) | n    | Adverse reactions in men (n = 290) |
|----------------------------------------|------|--------------------------------------|------|------------------------------------|
|                                        |      | After one vaccination | After both vaccination |      | After one vaccination | After both vaccination |
|                                        |      | No. | Frequency (%) | No. | Frequency (%) | No. | Frequency (%) | No. | Frequency (%) |
|                                        |      |     |              |     |              |     |              |     |              |
| Age (years)                            |      |     |              |     |              |     |              |     |              |
| 18-29                                  | 346  | 48  | 13.9         | 29  | 8.4          | 71  | 8             | 11.3 | 4             | 5.6 |
| 30-39                                  | 482  | 81  | 16.8         | 42  | 8.7          | 77  | 8             | 10.4 | 7             | 9.1 |
| 40-49                                  | 231  | 25  | 10.8         | 17  | 7.4          | 97  | 9             | 9.3  | 2             | 2.1 |
| 50-60                                  | 48   | 11  | 22.9         | 3   | 6.3          | 45  | 5             | 11.1 | 1             | 2.2 |
| Total service time (years)             |      |     |              |     |              |     |              |     |              |
| <5                                     | 373  | 58  | 15.5         | 29  | 7.8          | 106 | 10            | 9.4  | 5             | 4.7 |
| ≥5                                     | 734  | 107 | 14.6         | 62  | 8.4          | 184 | 20            | 10.9 | 9             | 4.9 |
| Education level                        |      |     |              |     |              |     |              |     |              |
| Junior College and below               | 359  | 50  | 13.9         | 21  | 5.8          | 87  | 6             | 6.9  | 1             | 1.1 |
| Undergraduate                          | 690  | 104 | 15.1         | 63  | 9.1          | 124 | 15            | 12.1 | 7             | 5.6 |
| Graduate                               | 58   | 11  | 19.0         | 7   | 12.1         | 79  | 9             | 11.4 | 6             | 7.6 |
| Position                               |      |     |              |     |              |     |              |     |              |
| Health professionals                   | 881  | 136 | 15.4         | 78  | 8.9          | 200 | 22            | 11.0 | 11            | 5.5 |
| Administrative support staff           | 226  | 29  | 12.8         | 13  | 5.8          | 90  | 8             | 8.9  | 3             | 3.3 |
| Professional titles                    |      |     |              |     |              |     |              |     |              |
| Internship or primary                  | 466  | 73  | 15.7         | 37  | 7.9          | 109 | 8             | 7.3  | 6             | 6.0 |
| Medium or higher                       | 641  | 92  | 14.4         | 54  | 8.4          | 181 | 22            | 12.2 | 8             | 4.4 |
| Body mass index (kg/m²)                |      |     |              |     |              |     |              |     |              |
| <24                                    | 876  | 139 | 15.9         | 68  | 7.8          | 126 | 10            | 7.9  | 2             | 1.6 |
| ≥24                                    | 231  | 26  | 11.3         | 23  | 10.0         | 164 | 20            | 12.2 | 12            | 7.3 |
| Underlying disease                     |      |     |              |     |              |     |              |     |              |
| No                                     | 1020 | 148 | 14.5         | 81  | 7.9          | 233 | 20            | 8.6  | 9             | 3.9 |
| Yes                                    | 87   | 17  | 19.5         | 10  | 11.5         | 57  | 10            | 17.5 | 5             | 8.8 |
| Take medication before vaccination     |      |     |              |     |              |     |              |     |              |
| No                                     | 1059 | 153 | 14.4         | 85  | 8.0          | 258 | 28            | 10.9 | 12            | 4.7 |
| Yes                                    | 48   | 12  | 25.0         | 6   | 12.5         | 32  | 2             | 6.3  | 2             | 6.3 |

(Continued)
### TABLE 2 | Continued

| Variables                                      | n  | Adverse reactions in women (n = 1107) | n  | Adverse reactions in men (n = 290) |
|------------------------------------------------|----|--------------------------------------|----|-----------------------------------|
|                                                |    | After one vaccination | After both vaccination |    | After one vaccination | After both vaccination |
| Adverse reactions to other vaccines            |    | No. | Frequency (%) | No. | Frequency (%) | No. | Frequency (%) | No. | Frequency (%) |
| No                                             | 1046 | 140 | 13.4 | 81 | 7.7 | 277 | 28 | 10.1 | 8 | 2.9 |
| Yes                                            | 61   | 25  | 41.0 | 10 | 16.4 | 13  | 2  | 15.4 | 6 | 46.2 |
| Worry about adverse reactions                  |    | No. | Frequency (%) | No. | Frequency (%) | No. | Frequency (%) | No. | Frequency (%) |
| No                                             | 472  | 41  | 8.7  | 24 | 5.1  | 171 | 6  | 3.5  | 7 | 4.1  |
| Yes                                            | 635  | 124 | 19.5 | 67 | 10.6 | 119 | 24 | 20.2 | 7 | 5.9  |
| Knowledge of inactivated vaccine being used in the hospital |    | No. | Frequency (%) | No. | Frequency (%) | No. | Frequency (%) | No. | Frequency (%) |
| Inactivated vaccine                            | 874  | 138 | 15.8 | 80 | 9.2  | 232 | 26 | 11.2 | 13 | 5.6  |
| Others                                         | 233  | 27  | 11.6 | 11 | 4.7  | 58  | 4  | 6.9  | 1 | 1.7  |
| Take vaccine for the family proactively        |    | Yes | 782  | 98 | 12.5 | 52  | 6.6 | 234 | 24 | 10.3 | 9 | 3.8 |
|                                                |    | No/Not sure | 325 | 67 | 20.6 | 39 | 12.0 | 56 | 6 | 10.7 | 5 | 8.9 |
| Get influenza vaccination                      |    | No   | 802  | 114 | 14.2 | 56 | 7   | 217 | 23 | 10.6 | 11 | 5.1 |
|                                                |    | Yes | 305  | 51  | 16.7 | 35 | 11.5 | 73  | 7  | 9.6  | 3 | 4.1  |
| Allergic reaction                              |    | No   | 1038 | 146 | 14.1 | 85 | 8.2  | 275 | 28 | 10.2 | 12 | 4.4 |
|                                                |    | Yes | 69   | 19  | 27.5 | 6  | 8.7  | 15  | 2  | 13.3 | 2 | 13.3 |
| Health status before vaccination               |    | Good | 1009 | 134 | 13.3 | 78 | 7.7  | 279 | 29 | 10.4 | 13 | 4.7 |
|                                                |    | General/Worse | 98  | 31  | 31.6 | 13 | 13.3 | 11  | 1  | 9.1  | 1 | 9.1 |
| Sleep quality before vaccination               |    | Good | 833  | 98  | 11.8 | 58 | 7.0  | 235 | 21 | 8.9  | 11 | 4.7 |
|                                                |    | General/Worse | 274 | 67  | 24.5 | 33 | 12.0 | 55  | 9  | 16.4 | 3 | 5.5 |

Statistically significant values at p < 0.05 are shown in bold.
double the number of occurrences of potential thrombotic events reported in women \((n = 19)\) than men \((n = 9)\) (18). In contrast, a cross-sectional study in Saudi Arabia showed that men were more likely to report fever, skin rash, and pain at the injection site following the first dose of the AstraZeneca (AZD1222) COVID-19 vaccine (19). Therefore, sex disparity in adverse reactions to vaccines may be related to the type of vaccine and the severity of the adverse reaction.

**Mechanism of Sex Differences in Vaccine Response**

The pathophysiology of sex differences in adverse reactions following immunization is multifactorial. Clear biological differences between the sexes can usually be attributed to immunological, hormonal, or genetic factors or a combination of the three. Adult females tend to have stronger inflammatory responses to vaccines than males, and these differences may result in both the female-biased efficacy of vaccines and female-biased adverse events following vaccination. Sex hormones modulate the function of immune cells, including β cells, which results in differential immune responses between the sexes. Estrogens have immune-suppressive effects at higher levels and immune-stimulant activity at lower levels (20, 21), while testosterone suppresses innate immune responses at all times. Females have two X chromosomes which carry many genes related to immune mechanisms, while males just have one. Angiotensin converting enzyme 2 (ACE2), a functional receptor for SARS-CoV-2, is encoded by its homologous gene (ACE2), which maps on chromosome X (Xp2.22) (22). Recent research has demonstrated that the angiotensin-converting enzyme-2 (ACE2) receptor is an essential port of cell entry for the spike (S) protein of SARS-CoV-2 (23). It has been reported that estrogen (17β-estradiol) inhibits ACE2 activity, but androgen upregulates the activity of ACE2 (24, 25).

Beyond the biological differences, a growing body of evidence supports gender-based social/behavioral differences in vaccine response, such as different comorbidity rates (e.g., obesity, hypertension, and cardiovascular diseases), smoking and drinking habits, educational levels, and societal roles (10). A recent study demonstrated that the expression of ACE2 increases under cigarette smoke exposure and inflammatory stimulation (26). The smoking rate is typically higher among men than among women (50.5 vs. 2.1%) according to the 2018 Global Adult Tobacco Survey (27). The prevalence of obesity among men was 2.7 times higher than that among women in this study. Women constitute the majority of nurses and caregivers both in hospitals and within families, with 70% of the world’s healthcare staff is composed of women. Women were more likely to perceive and/or report adverse reactions compared to men, leading to a higher response rate (28). In addition, social culture contexts, such as Confucian morals and socialistic norms, will be also related to disparities in health-seeking behavior and reporting adverse reactions between men and women (29, 30). Despite this recognition, there is little evidence demonstrating these effects. Further research is needed to clarify whether the observed sex differences are primarily due to a disproportionate share of unhealthy behavior between genders or are related to different immune responses or other factors.

**Methodological Considerations**

The main strengths of our study include the real-world design to better reflect real life, data collection using an active surveillance method, and very limited missing data. Sample representativeness was the main limitation of our study. The
sample was recruited from only one hospital, and the participants were likely to be younger and healthier than the general population. The majority of respondents were female. The selected bias may have resulted in an overestimation of the proportion of adverse reactions. Potential report and recall bias should also be noted, although all participants had been vaccinated within 7 weeks prior to completing the survey. Data were collected using self-administered questionnaires. No assessment was made as to whether the reported adverse reactions were related to vaccination. Finally, our measurements were performed at only a single point in time. We were unable to validate the anonymous survey. Moreover, this study does not reflect long-term exposure to factors that may be important for adverse reactions to the inactivated SARS-CoV-2 vaccine.

CONCLUSIONS

In conclusion, our study implies that the frequency of reported adverse reactions to the inactivated SARS-CoV-2 vaccine reflects long-term exposure to factors that may be important for vaccine acceptance in the female population during mass vaccination.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

REFERENCES

1. Available online at: https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines/ad groupsurvey=%7b%7d&glid=CwvKAjwzmHBhAxieAwAYj- JdhqjPFAI512AEXUA68OC070mRh05U3uEFdFVqk_x2XWNe2YWqbcCjCkCqAD_BwE
2. Smadja DM, Yue QY, Chocron R, Sanchez O, Lillo-Le Louet A. Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase. Eur Respir J. (2021) 16:2100956. doi: 10.1183/13993003.00956-2021
3. Rozenberg S, Vandrome J, Martin C. Are we equal in adversity? Does Covid-19 affect women and men differently? Maturitas. (2020) 138:62–8. doi: 10.1016/j.maturitas.2020.03.009
4. Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. (2020) 588:315–20. doi: 10.1038/s41586-020-2700-3
5. Tadoun F, Doyon-Plourde P, Rafferty E, MacDonald S, Sadarangani M, Quach C. Is there a difference in the immune response, efficacy, effectiveness and safety of seasonal influenza vaccine in males and females? - A systematic review. Vaccine. (2020) 38:444–59. doi: 10.1016/j.vaccine.2019.10.091
6. Garner-Spitzer E, Poellabauer EM, Wagner A, Guzek A, Zwaal I, Seidl-Friedrich C, et al. Obesity and sex affect the immune responses to tick-borne encephalitis booster vaccination. Front Immunol. (2020) 11:860. doi: 10.3389/fimmu.2020.00860
7. Zhang MX, Zhang TT, Shi GF, Cheng FM, Zheng YM, Tung TH, et al. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Rev Vaccines. (2021) 13:1–8. doi: 10.1080/14760584.2021.1925112
8. Spila Alegiani S, Alfonsi V, Appelgren EC, Ferrara I, Gallo T, Alcino C, et al. Active surveillance for safety monitoring of seasonal influenza vaccines in Italy, 2015/2016 season. BMC Public Health. (2018) 18:1401. doi: 10.1186/s12889-018-6260-5
9. Klein SL, Marriott I, Fish EN. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg. (2015) 109:9–15. doi: 10.1093/trstmh/tru167
10. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol. (2017) 33:577–99. doi: 10.1146/annurev-cellbio-100616-060718
11. Xiong X, Yuan J, Li M, Jiang B, Lu ZK. Age and gender disparities in adverse events following COVID-19 vaccination: real-world evidence based on big data for risk management. Front Med (Lausanne). (2021) 8:700014. doi: 10.3389/fmed.2021.700014
12. Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021. JAMA. (2021) 325:1101–2. doi: 10.1001/jama.2021.1967
13. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. (2021) 70:46–51. doi: 10.15585/mmwr.mm7002e1
14. Menui C, Klaeser K, May A, Poldiorti L, Capevadja J, Looua P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of Taizhou Hospital of Zhejiang Province in China (Reference No. K20210217, approved on 26 February 2021). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. Written informed consent was not obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

J-SZ and T-HT: conceptualization. M-XZ and T-HT: methodology. M-XZ, W-YY, and G-FS: investigation. M-XZ and G-FS: data curation. M-XZ: formal analysis and writing—original draft preparation. SQ and T-HT: writing—review, editing, visualization, and project administration. C-WC and H-XC: supervision. All authors have read and agreed to the published version of the manuscript.

ACKNOWLEDGMENTS

We would like to thank participants for their cooperation and support.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.731593/full#supplementary-material
Zhu et al. Sex Differences in SARS-CoV-2 Vaccine

Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. (2021) 21:939–49. doi: 10.1016/S1473-3099(21)00224-3

15. Iguchi T, Umdea H, Koijima M, Kanno Y, Tanaka Y, Kinoshita N, et al. Cumulative adverse event reporting of anaphylaxis after mRNA COVID-19 vaccine (Pfizer-BioNTech) injections in Japan: the first-month report. Drug Saf. (2021) 4:1–6. doi: 10.1007/s40264-021-01104-9 Online ahead of print.

16. Bae S, Lee YW, Lim SY, Lee JH, Lim JS, Lee S, et al. Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea. J Korean Med Sci. (2021) 36:e115. doi: 10.3346/jkms.2021.36.e115

17. Lee YW, Lim SY, Lee JH, Lim JS, Kwon S, et al. Adverse reactions of the second dose of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in Korea. J Korean Med Sci. (2021) 36:e153. doi: 10.3346/jkms.2021.36.e153

18. Tobaqiy M, Elkout H, MacLure K. Analysis of thrombotic adverse reactions of COVID-19 astrazeneca vaccine reported to eudravigilance database. Vaccines. (2021) 9:393. doi: 10.3390/vaccines9040393

19. AlBahrani S, AlBarraK A, Alghamdi OA, Abdullah Alghamdi M, Hakami FH, Abaadi AKA, et al. Safety and reactogenicity of the ChAdOx1 (AZD1222) COVID-19 vaccine in vaccine in Saudi Arabia. Int J Infect Dis. (2021) 25:S1201-9712(21)00608-1. doi: 10.1016/j.ijidd.2021.07.052

20. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. (2016) 16:626–38. doi: 10.1038/nri.2016.90

21. Del Valle DM, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. (2020) 26:1636–43. doi: 10.1038/s41591-020-1051-9

22. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ, et al. human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. (2000) 275:33238–43. doi: 10.1074/jbc.M002615200

23. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. (2020) 181:271–80.e8. doi: 10.1016/j.cell.2020.02.052

24. Liu J, Ji H, Zheng W, Wu X, Zhu JJ, Arnold AP, et al. Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17β-oestradiol-dependent and sex chromosome-independent. Biol Sex Differ. (2010) 1:6. doi: 10.1186/2042-6410-1-6

25. Viveiros A, Rasmussen J, Vu J, Mulvagh SL, Yip CY, Norris CM, et al. Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones. Am J Physiol Heart Circ Physiol. (2021) 320:H296–304. doi: 10.1152/ajpheart.00755.2020

26. Smith JC, Saussville EL, Girish V, Yuan ML, Vasudevan A, John KM, et al. Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract. Dev Cell. (2020) 53:514–29.e3. doi: 10.1016/j.develcel.2020.05.012

27. World Health Organization (WHO). Global Adult Tobacco Survey (GATS). Fact sheet China 2018. https://www.who.int/docs/default-source/wpro-documents/countries/china/2018-gats-china-factsheet-cn-en.pdf?sfvrsn=3f4e2da9_2. (Accessed on 30 Apr 2021)

28. de Vries ST, Denig P, Ekhart C, Burgers JS, Kleefstra N, Mol PGM, et al. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study. Br J Clin Pharmacol. (2019) 83:1507–15. doi: 10.1111/bcp.13923

29. Thompson AE, Anisimowicz Y, Miedema B, Hogg W, Wodchis WP, Aubrey-Bassler K. The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study. BMC Fam Pract. (2016) 17:38. doi: 10.1186/s12875-016-0440-0

30. Shek DT Yu L, Fu X. Confucian virtues and Chinese adolescent development: a conceptual review. Int J Adolesc Med Health. (2013) 25:335–44. doi: 10.1515/ijamb-2013-0031

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zhu, Zhang, Chien, Yang, Shi, Qiu, Tung and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.